Bernard J. Zovighian - 09 Nov 2026 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
09 Nov 2026, 16:29:16 UTC
Prior SEC filing
27 Jul 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
Linda J. Park, Attorney-in-Fact
Filing notes and source

Key filing fact

Bernard J. Zovighian filed Form 4 for Edwards Lifesciences Corp (EW) on 09 Nov 2026.

Key facts

  • This page summarizes Bernard J. Zovighian's Form 4 filing for Edwards Lifesciences Corp (EW).
  • 4 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 09 Nov 2026, 16:29.

Change

  • Previous filing in this sequence was filed on 27 Jul 2026.
  • Current net transaction value: -$2,379,779.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001665141 Primary reporting owner

Zovighian Bernard J

Relationship
CEO, Director
Address
ONE EDWARDS WAY, IRVINE
Signature
Linda J. Park, Attorney-in-Fact
Signature date
09 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EW transaction

Common Stock

Options Exercise

Transaction value
Shares
+23,100
Change %
+23%
Price
$72.68*
Shares after
121,945
Date
09 Nov 2026
Ownership
Direct
Footnotes
F1
EW transaction

Common Stock

Sale

Transaction value
-$949,489
Shares
-9,184
Change %
-7.5%
Price
$103.39
Shares after
112,761
Date
09 Nov 2026
Ownership
Direct
Footnotes
F1, F2
EW transaction

Common Stock

Sale

Transaction value
-$1,430,291
Shares
-13,916
Change %
-12%
Price
$102.78
Shares after
98,845
Date
09 Nov 2026
Ownership
Direct
Footnotes
F1, F3
EW holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
3,734
Date
09 Nov 2026
Ownership
401(k)
EW holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
8,916
Date
09 Nov 2026
Ownership
By Trust

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EW transaction Derivative

Employee Stock Option (Right to Acquire)

Options Exercise

Transaction value
Shares
-23,100
Change %
-50%
Price
$0.000000*
Shares after
23,100
Date
09 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
23,100
Exercise price
$72.68
Footnotes
F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 28, 2026.

Footnote F2

This transaction was executed in multiple trades at prices ranging from $103.18 to $103.66 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Footnote F3

This transaction was executed in multiple trades at prices ranging from $102.17 to $103.16 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Footnote F4

These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC remarks

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .